RGD-functionalized cannabidiol lipid nanoparticles improve brain delivery and alleviate cognitive and metabolic dysfunction via gut-brain axis modulation in an Alzheimer's disease model - 19/07/26
Abstarct |
Background |
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and neuronal loss. Evidence links gut–brain axis dysfunction and metabolic disturbances to AD. Although cannabidiol (CBD) has neuroprotective effects, its use is limited by poor bioavailability and brain delivery.
Methods |
Arginylglycylaspartic acid (RGD)-functionalized, CBD-loaded lipid nanoparticles (CBD/LNP-RGD) were developed to enhance targeted delivery across the blood–brain barrier (BBB) via integrin α v β 3 -mediated transcytosis. Cellular uptake and BBB permeability were evaluated in vitro . Anti-inflammatory and antioxidant effects were assessed in Aβ/LPS-induced models. In vivo efficacy was examined using cognitive-behavioral tests, including the novel object recognition and the Morris water maze. Metabolic parameters, histopathology, synaptic protein expression, and gut barrier integrity were also evaluated.
Results |
CBD/LNP-RGD demonstrated a 3-fold increase in cellular uptake and a 65% enhancement in BBB transport compared to non-targeted formulations. Treatment significantly reduced pro-inflammatory cytokines (i.e., IL-6 and TNF-α, p < 0.001) and intracellular reactive oxygen species ( p < 0.001). In vivo , CBD/LNP-RGD improved cognitive performance comparable to Donepezil ( p < 0.001). Additionally, it normalized glycemic control, insulin resistance, and triglyceride levels without hepatic or renal toxicity. At the tissue level, CBD/LNP-RGD reduced Aβ and tau pathology, restored short-chain fatty acids, preserved hippocampal neuronal integrity, and upregulated synaptophysin and PSD-95 proteins. Enhanced intestinal barrier function was evidenced by increased expression of tight junction proteins ZO-1 and occludin.
Conclusions |
CBD/LNP-RGD represents a multifunctional nanotherapeutic platform that improves brain delivery and exerts neuroprotective, anti-inflammatory, antioxidant, and metabolic regulatory effects. Its ability to modulate both central pathology and the gut–brain axis highlights its potential as a disease-modifying strategy for Alzheimer’s disease.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | CBD/LNP-RGD enhanced in vitro uptake, BBB transport, and in vivo brain delivery. |
• | CBD/LNP-RGD attenuated oxidative stress in inflamed Alzheimer's disease models. |
• | CBD/LNP-RGD improved cognition and metabolic balance in Alzheimer's disease rats. |
• | CBD/LNP-RGD restored gut integrity and neuroplasticity in Alzheimer's disease rats. |
Keywords : Alzheimer’s disease, Blood–brain barrier, Cannabidiol, Memory, RGD targeting
Plan
Vol 201
Article 119724- août 2026 Retour au numéro
Article précédent
- Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer
- Jihye Kim, Ju-Yeon Choi, Jun-Hyeong Seo, Young-Jae Cho, Ji-Yoon Ryu, Jae Ryoung Hwang, Jung-Joo Choi, Jeong-Won Lee
- Cardioprotective potential of Fridericia platyphylla (Cham.) L.G. Lohmann: Phytochemical characterization and experimental evidence
- Andressa Coelho Ferreira, Raphael Furtado Marques, Jhonata Costa Moura, Ellen Caroline da Silva Penha, Carine Novaes Paes Leme, Bianca de Fátima Assunção Sodré, Carlos Henrique de Barros da Costa Sobrinho, Jhonathas Aparecido Rodrigues Brito, Júlia Karla de Albuquerque Melo Xavier, Cláudia Quintino Rocha, Carlos Alberto Alves Dias Filho, Marilene de Oliveira da Rocha Borges, Rachel Melo Ribeiro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?